Loading clinical trials...

Azacytidine, Bendamustine, Piamprizumab in Refractory/Relapsed B-cell Non-Hodgkin's Lymphoma | Clinical Trials | Clareo Health

UNKNOWNPHASE1/PHASE2

Azacytidine, Bendamustine, Piamprizumab in Refractory/Relapsed B-cell Non-Hodgkin's Lymphoma

An Open Label, Single Arm, Phase I/II in the Combination of Azacytidine, Bendamustine and Piamprizumab in Refractory/Relapsed B-cell Non-Hodgkin's

NCT04897477•Chinese PLA General Hospital

View on ClinicalTrials.gov

Summary

This is an open label, single arm, phase I/II for patients with r/r Non-Hodgkin's Lymphoma . The purpose is to evaluate the safety and efficacy of the combination with Azacytidine, Bendamustine and Piamprizumab

Eligibility

Age

18 - 80 years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•1. Age ≥18 and ≤80 years
•2. Performance status (ECOG) between 0 and 3.
•3. Histologically confirmed B-cell non-Hodgkin lymphoma (NHL), including the following types defined by WHO 2016.
•4. Refractory disease or relapsed after treatment with ≥2 lines of chemotherapy and either having failed autologous HSCT or being ineligible for or not consenting to autologous HSCT; or not suitable for CAR T treatment or resistance, progression or relapse after CAR T treatment; or CAR T pre-culturing losers can also be enrolled.
•5. Adequate organ function.
•6. An adequate bone marrow reserve.

Exclusion Criteria

•8. Informed consent/assent requiring that all patients have the ability to understand and the willingness to provide written informed consent.
•9. Life expectancy \> 12 weeks.
•10. Patients with definite involvement of the gastrointestinal tract, and patients with central nervous system (CNS) by PETCT and MRI involvement were allowed to enrolled in this clinical study.
•1. Pregnant or lactating women.
•2. Uncontrolled medical disorders, active bacterial, viral infection or treponema pallidum infection and so on.
•3. Requirement for urgent therapy due to tumor mass effects such as respiratory obstruction or blood vessel compression.
•4. Current or expected need for systemic corticosteroid therapy.
•5. Any organ failure.
•6. Patients with a second tumor requiring therapy or intervention.
•7. Subjects considered unlikely to complete all protocol-required study visits or procedures, including follow-up visits, or comply with the study requirements for participation according to the investigator's judgement.
+2 more criteria

Locations (2)

Biotherapeutic Department of Chinese PLA General Hospital

Beijing, Beijing Municipality, China

Biotherapeutic Department of Chinese PLA General Hospital

Beijing, China

Key Dates

Start Date

April 22, 2021

Primary Completion Date

April 23, 2022

Completion Date

April 23, 2023

Last Updated

May 21, 2021

Enrollment

ESTIMATED participants

Conditions

Non-hodgkin Lymphoma,B Cell

Interventions

Azacytidine, Bendamustine and Piamprizumab

DRUG

Contacts

Weidong Han, M.D.

CONTACT

+861055499341 hanwdrsw@sina.com

SARcopenia and Simplified Geriatric Assessment in Lymphoma Patients Undergoing CAR-T Cell Therapy: the FIL_SAR-CAR Project

NCT06156774

Non-hodgkin Lymphoma,B Cell

View study

COMPLETEDPHASE2

Acalabrutinib With Rituximab and Lenalidomide in Relapsed/Refractory B-cell Non-Hodgkin Lymphoma

NCT04094142

Non-hodgkin Lymphoma,B Cell

View study

UNKNOWNPHASE1/PHASE2

CART-19 Immunotherapy in Mantle Cell Lymphoma

NCT02081937

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: May 21, 2021Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions